GSK plc Sponsored ADR (GSK)
GSK lifts profit outlook after strong quarter and upbeat broker reaction
GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% to 1,707p after the pharmaceutical group raised its full-year guidance and delivered quarterly results that topped forecasts across almost every metric. The upbeat figures, helped by a strong performance in Specialty Medicines and vaccines, also prompted positive analyst commentary, with Jefferies reaffirming its 'buy' rating and setting a price target of 2,000p.
GSK Raises Guidance After Sales, Earnings Growth
The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.
GSK hikes outlook as sales and earning grow faster than expected
GSK PLC (LSE:GSK, NYSE:GSK) raised its outlook for the full year after beating expectations with third-quarter revenues and earnings per share. Group revenues for the FTSE 100 drugmaker came in at £8.55 billion for the quarter to the end of September, up 7% on the same period last year and topping the average City forecast of £8.28 billion.
GSK raises 2025 sales forecast after strong growth in specialty medicines
GSK raised its 2025 sales expectations on Wednesday after third-quarter results beat expectations, driven by double-digit growth in its specialty medicines, including HIV and oncology.
Here's Why GSK (GSK) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK cancer drug wins EU orphan status for small-cell lung cancer
GSK PLC (LSE:GSK, NYSE:GSK) has secured Orphan Drug Designation in the European Union for GSK5764227, also known as GSK'227, a B7-H3-targeted antibody-drug conjugate being tested in small-cell lung cancer (SCLC). The decision is based on early clinical signals from the phase I ARTEMIS-001 study, where patients with extensive-stage SCLC who had relapsed after prior therapy showed durable responses.
Here's Why GSK (GSK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
GSK plc aka GlaxoSmithKline is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved market sentiment, with growth led by Specialty Medicines and geographic expansion in Europe. Unlike peers, GSK faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher valuation multiples.
GSK's Hidden Growth Engines Beyond HIV And Oncology
GSK continues to successfully develop its oncology franchise. So, sales of its "gem" in the treatment of myelofibrosis, called Ojjaara, reached $183 million in the second quarter of 2025, increasing by 71% year-on-year. In addition, GSK increased its 2025 sales growth outlook from a "low-double digit percentage" to a "low-teens percentage."
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GSK chief exec Emma Walmsley to leave in January
GSK PLC (LSE:GSK, NYSE:GSK) chief executive Dame Emma Walmsley will step down from 1 January next year after almost nine years in the role. The pharmaceutical group has promoted its chief commercial officer, Luke Miels, as CEO designate.
